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BACKGROUND: Over 8000 new pancreatic cancers are diagnosed annually in the UK; most at an advanced stage, with only 3% 5-year
survival. We aimed to identify and quantify the risk of pancreatic cancer for features in primary care.
METHODS: A case–control study using electronic primary care records identified and quantified the features of pancreatic cancer.
Cases, agedX40 in the General Practice Research Database, UK, with primary pancreatic cancer were matched with controls on age,
sex and practice. Putative features of pancreatic cancer were identified in the year before diagnosis. Odds ratios (OR) were calculated
for features of cancer using conditional logistic regression. Positive predictive values (PPV) were calculated for consulting patients.
RESULTS: In all, 3635 cases and 16 459 controls were studied. Nine features were associated with pancreatic cancer (all Po0.001
except for back pain, P¼ 0.004); jaundice, OR 1000 (95% confidence interval (CI) 4 302 500); abdominal pain, 5 (4.4, 5.6); nausea/
vomiting, 4.5 (3.5, 5.7); back pain, 1.4 (1.1, 1.7); constipation, 2.2 (1.7, 2.8); diarrhoea, 1.9 (1.5, 2.5); weight loss, 15 (11, 22); malaise,
2.4 (1.6, 3.5); new-onset diabetes 2.1 (1.7, 2.5). Positive predictive values for patients agedX60 were o1%, apart from jaundice at
22% (95% CI 14, 52), though several pairs of symptoms had PPVs 41%.
CONCLUSION: Most previously reported symptoms of pancreatic cancer were also relevant in primary care. Although predictive values
were small – apart from jaundice – they provide a basis for selection of patients for investigation, especially with multiple symptoms.
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Pancreatic tumours account for 2.6% of all newly diagnosed
cancers in the UK with B8000 new diagnoses and deaths each
year, making it the fifth most common cause of cancer death in the
UK (Cancer Research UK, 2008). Worldwide there are an estimated
279 000 new cases per year. It has a very poor prognosis, with few
patients eligible for potentially curative surgery, leading to a 5-year
survival of around 3% (Rachet et al, 2009). The incidence increases
with age, with over 75% of new cases occurring in those aged 65
and over. Most tumours originate from the exocrine part of the
pancreas. Endocrine tumours are rare but generally have a much
more favourable prognosis. Despite the emergence of promising
biomarkers for diagnosis there are no screening tests currently
available, so diagnosis depends upon presentation with symptoms.
The symptoms of primary pancreatic cancer have only been
described in secondary care studies. It occurs rarely in primary
care: a full time general practitioner (GP) would see on average
only one case every 5 years (NICE, 2001). Studies have mostly
been retrospective surgical case series, with the potential for recall
bias; perforce, they study patients late in the natural course of
their disease. Abdominal pain is reported in up to 80% of patients
(Takhar et al, 2004). Obstructive jaundice, which occurs when the
biliary tract becomes blocked by the tumour, occurs in 16–85%:
(Klamer and Max, 1982; Mannell et al, 1986; Manabe et al, 1988;
Furukawa et al, 1996; Wilson et al, 2000; Elli et al, 2003) it is
usually a feature of advanced disease. Weight loss is also reported
in 3–82%, again generally denoting advanced disease (Klamer and
Max, 1982; Mannell et al, 1986; Furukawa et al, 1996; Elli et al,
2003). Pancreatitis and thrombo-phlebitis have also been described
(BakkevoldK et al, 1992; Picozzi, 2005) Diabetes may follow if
pancreatic damage is considerable (Everhart and Wright, 1995).
Other symptoms, such as loss of taste, pruritus, psychological
disturbances or skin changes, have been reported for up to 2 years
before onset of pain or jaundice (Picozzi, 2005).
UK guidance for the selection of patients for urgent investiga-
tion of suspected cancer has no specific section relating to
pancreatic cancer: instead, recommendations for oesophageal,
gastric and pancreatic cancer are merged, with criteria for upper
gastrointestinal endoscopy predominant (NICE, 2005). Symptoms
potentially representing one of these three cancer sites recom-
mended for urgent investigation are obstructive jaundice, persis-
tent vomiting, anaemia or an unexplained loss of weight. In a
recent audit of 345 upper gastrointestinal urgent referrals based on
these recommendations in London, 36 (11.4%) upper gastro-
intestinal cancers were identified, 13 being pancreatic (Patel et al,
*Correspondence: Professor W Hamilton;
E-mail: willie.hamilton@pcmd.ac.uk
Revised 13 April 2012; accepted 13 April 2012; published online 22 May
2012
British Journal of Cancer (2012) 106, 1940–1944
& 2012 Cancer Research UK All rights reserved 0007 – 0920/12
www.bjcancer.com
C
lin
ic
a
l
S
tu
d
ie
s
2011). Most were advanced disease. The authors called for better
selection of patients for investigation: this requires study of the
symptoms of pancreatic cancer in primary care. We sought to
identify features of pancreatic cancer, and to quantify their risk,
in patients presenting to primary care.
MATERIALS AND METHODS
This was a case–control study using data from the General Practice
Research Database (GPRD) in the UK. The GPRD maintains an
anonymised copy of participating practices’ medical records: these
contain full details of the patient, including all consultations,
recorded symptoms, investigations and diagnoses. The data are
subject to stringent checks on validation and quality, and they are
regarded as high quality in terms of accuracy and completeness
and validity of diagnoses (Herrett et al, 2010; Khan et al, 2010).
We have previously used similar methods for several cancer
diagnostic studies (Hamilton, 2009).
Identification of cases and controls
A list of 25 pancreatic tumour diagnostic codes (available from the
authors) was collated from the GPRD master code library. This has
B100 000 codes covering all events in primary care. Some codes
specifically identified the histological subtype, but most were
unspecified, such as ‘malignant neoplasm of pancreas’. Staff from
the GPRD identified all patients aged 40 years and over with a
pancreatic tumour diagnosed between 1st January, 2000 and 31st
December, 2009 and with at least 1 year of data meeting their
quality standards before the first diagnostic code. For each case,
the GPRD identified up to five controls, matched to the case by
year of birth, sex and practice and randomly selected using a
computer-generated sequence. We chose five controls for max-
imum power within the GPRD’s constraints as to total database
size. We excluded cases and controls if they had no consultations
in the year before diagnosis in the case (the index date). Controls
were excluded if they had ever had pancreatic cancer.
Selection of possible features of pancreatic cancer
We studied all symptoms, physical signs or abnormal investiga-
tions compiled from the pancreatic cancer literature, supplemen-
ted by discussion with two pancreatic cancer charities (full list
available from authors). For simplicity, these are called ‘features’
from now on. Libraries of codes relating to these were collated. We
also identified all codes for fractures, as a test for any recording
bias between cases and controls (making the assumption that the
fracture rate would be approximately equal). Occurrences of these
features in the year before the index date were identified. Features
were only retained for further study if they occurred in X5% of
cases or controls. Repeat attendances with the same symptom were
also retained if the subsequent consultation also occurred inX5%
of cases or controls. We defined new-onset diabetes as a code for
diabetes, or a random blood glucose above the local laboratory’s
normal range, without similar codes more than 1 year before the
index date. For laboratory tests, we considered patients without a
test to be the same status as those with a normal result, making our
binary variable abnormal result/ no abnormal result. We defined
abnormal liver function as any liver enzyme above the normal
range, and raised inflammatory markers as either abnormal
erythrocyte sedimentation rate or C-reactive protein, as there
were too few plasma viscosity results.
Analysis
Univariable analysis of differences between cases and controls
was undertaken using conditional logistic regression to account
for the matching. Variables independently associated with
pancreatic cancer with a P-value o0.1 were entered into
multivariable analyses. Multivariable regressions were performed
in stages, initially collecting similar variables together, such as
those reflecting abdominal pain. Significant variables then entered
a second stage, grouping variables into abdominal symptoms,
other symptoms, physical signs and investigations. For these two
stages, a threshold P-value ofo0.05 was used. The final model was
derived from all variables surviving the earlier stage regressions,
and used a threshold P-value ofo0.01. All rejected variables were
checked to see if they added anything to the final model. Lastly,
nine clinically plausible interactions were tested.
Calculation of positive predictive values (PPVs)
It was possible to calculate PPVs for the risk of pancreatic cancer
in patients consulting in primary care using Bayes’ theorem
(Knottnerus, 2002). In this, the posterior odds of disease¼ the
prior odds  the likelihood ratio. For the prior odds we used the
age-specific national incidence rate of pancreatic cancer for 2008
(Cancer Research UK, 2008). As all 3635 cases analysed had
consulted in primary care, but only 16 459 of 17 913 (92.1%)
controls had consulted in the study period, we divided the
posterior odds by 0.921 to give predictive values for the consulting
population. Analyses were performed using Stata (version 11)
(Stata Statistical Software, 2010).
RESULTS
We were initially supplied with 3647 cases and 17 977 controls, as
1207 cases could not be matched to five controls. The application
of exclusions is shown in Figure 1.
Of the 3635 cases included in the analyses, 98 (2.7%) had a
specific code for an endocrine tumour, though 2342 (64.2%), had a
generic label and some of these may have been endocrine. The
demographic features of cases are shown in Table 1, and the
univariable results for selected clinical features are shown in
Table 2. Sixty five (1.8%) of cases and 297 (1.8%) of controls had a
record of a fracture. In the year before diagnosis, cases presented
to primary care twice as frequently as controls: cases median 18;
interquartile range (IQR) 11, 27: controls median 9 (IQR) 4, 15.
Multivariable analysis results are shown in Table 3. One
antagonistic interaction term is included: abdominal pain with
jaundice. This can probably be explained clinically by an
alternative diagnosis of gallstones, which also may have abdominal
pain and jaundice as presenting features. External interaction
terms (testing whether features were more or less strongly
associated with cancer according to age, sex and smoking habits)
were not significant.
Figure 2 shows PPVs for pancreatic cancer for the symptoms
shown to be independently associated in multivariable analysis –
individually, when repeated and in combination with another
symptom for patients aged X60 years of either sex. This age
was chosen to allow over 80% of the pancreatic cancer population
to be shown in a single figure. For jaundice with constipation,
diarrhoea, loss of weight or malaise, more than 40 cases but no
controls had the combination; while strictly speaking undefined,
the PPV must logically be very high and so it has been set as
410%. One subgroup analysis by age was undertaken. Patients
aged X70 (the older half of the cohort) had PPVs for most
symptoms 1.5 to 4.5 times higher than those for patients under
70 years of age.
DISCUSSION
Summary of main findings
This is the first study of the clinical features of pancreatic cancer in
primary care. Most of the symptoms reported from secondary care
studies were also strongly associated with pancreatic cancer in
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primary care. However, the risk of pancreatic cancer with these
features – other than jaundice – was low, reflecting the rarity of
pancreatic tumours and that many of the symptoms are common
in benign conditions. The risk of an underlying pancreatic cancer
with these symptoms was higher in older patients, and in patients
with multiple symptoms.
Strengths and limitations of the study
This study is large, and uses primary care data. This is crucial:
selection of patients for investigation is performed by clinicians in
primary care, so primary care data must be used to illuminate the
selection process. The GPRD is considered by many to be the ’gold
standard’ of longitudinal patient databases from primary care. It
has been used in nearly 1000 research papers published in peer-
reviewed journals and its validity has been well documented
(Jick et al, 1991; Jick et al, 2003; Fombonne et al, 2004; Herrett
et al, 2010; Khan et al, 2010). The patient population in the
database is also broadly representative of the UK population.
Additionally, laboratory results are transmitted directly to the
database, allowing us to use the local normal range to identify
abnormal results.
We could not check the accuracy of diagnosis in the cases by
histology, or determine the staging. Linkage to cancer registries is
now possible, though only for a part of the GPRD. Most cases had
multiple records of a pancreatic neoplasm. It is unlikely that such a
serious disease would be recorded incorrectly with any frequency.
Total cases and controls
n =21 624
Cases
n =3647
Not of pancreatic
origin n =10
Controls
n =17 977
No data in year before
diagnosis n =1414
Case excluded n =40
Diagnosis of 
pancreatic cancer
n =64
No matched controls in
group who had 
consulted n =2
Figure 1 Application of exclusion criteria for cases and matched
controls. Conditional logistic regression requires a minimum of one case
and one matched control in each set, so if the case or all the controls are
excluded than the remaining set members must also be discarded.
Table 2 Frequency of selected features in cases and controls in the
whole study population
Clinical
feature
Cases,
n (%),
n¼3635
Controls,
n (%),
n¼ 16 459
LR
(95% CI)
PPV in
percenta
(95% CI)
Symptoms
Abdominal
pain
1540 (42.4) 1004 (6.1) 7.0 (6.5–7.5) 0.2 (0.19–0.22)
Nausea/
vomiting
590 (16.2) 408 (2.5) 6.6 (5.8–7.4) 0.19 (0.17–0.21)
Back pain 452 (12.4) 1007 (6.1) 2.0 (1.8–2.3) 0.06 (0.05–0.07)
Constipation 427 (11.8) 555 (3.4) 3.5 (3.1–3.9) 0.1 (0.09–0.11)
Diarrhoea 385 (10.6) 539 (3.3) 3.2 (2.9–3.7) 0.09 (0.08–0.11)
Weight loss 353 (9.7) 105 (0.6) 15.2 (12.3–18.9) 0.44 (0.36–0.55)
Malaise 187 (5.1) 197 (1.2) 4.3 (3.5–5.2) 0.12 (0.1–0.15)
Signs
Jaundice 1110 (30.5) 10 (0.1) 502.6 (269.9–935.7) 12.9 (7.89–27.1)
Diseases
New-onset
diabetes
804 (22.1) 1201 (7.3) 3.0 (2.8–3.3) 0.09 (0.08–0.10)
Investigations
Abnormal
liver function
1834 (50.5) 1506 (9.2) 5.5 (5.2–5.8) 0.16 (0.15–0.17)
Low
haemoglobin
728 (20.0) 978 (5.9) 3.4 (3.1–3.7) 0.1 (0.09–0.11)
Raised
inflammatory
markers
892 (24.5) 734 (4.5) 5.5 (5.0–6.0) 0.16 (0.15–0.17)
Abbreviations: CI¼ confidence interval; LR¼ likelihood ratio; PPV¼ positive predic-
tive value. aPPV in the consulting population.
Table 3 Multivariable analysis of the clinical features of pancreatic cancer
Variable Odds ratio (95% CI) P-value
Symptoms
Loss of weight 15 (11, 22) o0.001
Abdominal pain 5 (4.4, 5.6) o0.001
Nausea or vomiting 4.5 (3.5, 5.7) o0.001
Constipation 2.2 (1.7, 2.8) o0.001
Malaise 2.4 (1.6, 3.5) o0.001
Diarrhoea 1.9 (1.5, 2.5) o0.001
Back pain 1.4 (1.1, 1.7) 0.004
Signs
Jaundice 1000 (430, 2500) o0.001
Diseases
Diabetes 2.1 (1.7, 2.5) o0.001
Interaction term
Jaundice with abdominal pain 0.13 (0.05, 0.35) o0.001
Abbreviation: CI¼ confidence interval.
Table 1 Characteristics of patients in primary care with pancreatic
cancer (cases) and matched controls. Figures are number (percentage)
Cases
Total Females Males Controls
Age in years n¼ 3635 n¼ 1892 n¼ 1743 n¼ 16 459
40–49 107 (2.9) 43 (40.2) 64 (59.8) 422 (2.6)
50–59 529 (14.5) 234 (44.2) 295 (55.8) 2239 (13.6)
60–69 829 (22.8) 369 (44.5) 460 (55.5) 3755 (22.8)
70–79 1212 (33.4) 654 (53.9) 558 (46.1) 5702 (34.6)
80 and over 958 (26.4) 592 (61.8) 366 (38.2) 4341 (26.4)
Pancreatic cancer diagnosis in primary care
S Stapley et al
1942
British Journal of Cancer (2012) 106(12), 1940 – 1944 & 2012 Cancer Research UK
C
lin
ic
a
l
S
tu
d
ie
s
The most significant limitation of the study is that we had to rely
upon the accurate recording by GPs of both symptoms and
diagnoses. Under-recording of symptoms or signs may have led to
some features, which may be genuinely associated with pancreatic
cancer, such as deep vein thrombosis or steatorrhoea, not being
identified in this study. One particular concern is that symptoms
may be recorded in an inaccessible part of the GPRD – the
so-called ‘free-text’ area. This is possible, though a recent study
of ovarian cancer identified relatively little hidden data in these
fields (Tate et al, 2011). However, when calculating likelihood
ratios and PPVs, under-recording is only important if the
proportion of under-recording was differentially higher in either
cases or controls. We have no evidence to suggest this is the case.
Comparison with existing literature
The prevalence of the most common symptoms of pancreatic
cancer was lower than in previous secondary care studies (Krech
and Walsh, 1991; Bakkevold et al, 1992; Gullo et al, 2001; Holly
et al, 2004; Porta et al, 2005). This may well reflect different
symptom experience early in the disease – especially in primary
care. There are two possible alternative explanations. The first is
under-recording of symptoms, as discussed earlier; the second is
that most previous studies directly interviewed patients after
diagnosis. Such methods may be subject to recall bias and usually
uncover higher rates of symptom reporting than do studies using
indirect methods such as ours. One UK questionnaire-based study,
which compared symptom recording in pancreatic disease by GPs
to symptom recording by health professionals in secondary care,
found prevalence figures similar to this study (Virlos et al, 2005).
Our finding of more frequent attendances mirrors reports in the
National Cancer patient Experience Survey, where 41% of
pancreatic cancer patients reported consulting their GP at least
three times before diagnosis (Lyratzopoulos et al, 2012).
Implications for clinical practice and future research
Our results should help GPs decide which patients to refer for
further investigation. A fifth of patients over 60 years with
recorded jaundice will have pancreatic cancer: this figure would
justify urgent referral. Current NICE guidance recommends urgent
referral only for obstructive jaundice, but the results from this
study would suggest that investigation for jaundice per se is
warranted, unless there is a clear alternative cause (NICE, 2005).
Even if no malignancy is uncovered by investigation, a common
alternative explanation for jaundice is stones in the biliary system,
and these are also worth identifying without undue delay.
Similarly, loss of weight had moderate PPVs when accompanied
by a second symptom from Table 3. Arguably, such patients could
also be considered for investigation. One problem is that
ultrasonography is excellent at visualising the biliary tree, but
CT scanning is preferred for imaging the pancreas itself – thus,
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0.1
(0.1, 0.1)
0.2
(0.2, 0.2)
0.2
(0.2, 0.2)
0.2
(0.2, 0.2)
0.2
(0.2, 0.3)
0.3
(0.3, 0.4)
0.3
(0.3, 0.4)
21.6
(14,52)
PPV as a
single
symptom  
0.2
(0.1, 0.2)
0.3
(0.2, 0.4)
0.2
(0.1, 0.3)
0.3
(0.2, 0.4)
0.3
(0.2, 0.6)
0.3
(0.2, 0.5)
0.4
(0.3, 0.5)
2.0
(1.0, 4.3)
8.9
–
Back pain
0.4
(0.3, 0.5)
0.4
(0.3, 0.6)
0.5
(0.3, 0.9)
0.7
(0.5, 1.0)
0.9
(0.7, 1.1)
1.6
(1.0, 2.9)
22.3
–
New onset
diabetes
0.2
(0.1, 0.3)
0.3
(0.1, 0.5)
0.2
(0.2, 0.3)
0.4
(0.3, 0.5)
2.7
–
>10
–
Diarrhoea
0.3
(0.2, 0.5)
0.6
(0.4, 0.8)
0.5
(0.4, 0.7)
1.5
(0.8, 3.0)
>10
–
Constipation
0.5
(0.3, 0.8)
0.6
(0.4, 0.8)
0.9
(0.4, 2.1)
>10
–
Malaise
0.9
(0.7, 1.2)
2.2
(1.1, 4.6)
14.6
–
Nausea or
vomiting
1.0 2.5
(1.5, 4.4)
15.0
–
Abdominal
pain
(0.8, 1.2)
>10
–
Loss of
weight
31.6
–
Jaundice
0.8
(0.7, 1.0)
Figure 2 Positive predictive values (95% CIs) for pancreatic cancer in men and women aged over 60 for individual risk markers and for pairs of risk
markers in combination. (1) The top figure in each cell is the positive predictive value when both features are present. The two smaller figures represent the
95% CIs for the positive predictive value. These have not been calculated when any cell in the 2 2 table was below 5 (invariably this was because too few
controls had both features). (2) The yellow shading is for pairs of symptoms with a positive predictive value over 1%; the amber shading is when the positive
predictive value is above 2.0%, and the red shading is for positive predictive values above 5.0%. (3) The jaundice/jaundice intersect is the positive predictive
value for pancreatic cancer when a patient has attended at least twice with jaundice. The same is true for abdominal pain and back pain.
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non-jaundiced patients would probably require the latter form of
imaging. Although more expensive than ultrasonography, CT
scanning may identify a cause for the symptoms should the
pancreas appear normal.
CONCLUSION
Although current mortality from pancreatic cancer is very high in
the UK, other European countries have better outcomes from the
cancer (Abdel-Rahman et al, 2009). It is not known if these better
outcomes arise from improved diagnostics or better treatment, or
both, but it gives some hope that the current dismal prognosis can
be improved somewhat. Our figures can guide GPs in selection of
patients for urgent investigation. Even though no new major
findings have emerged, this study provides primary care evidence
for the forthcoming revision of the UK NICE referral guidance.
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